Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast cream in atopic dermatitis
NCT03916081Phase 2Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- May 2019
- Primary completion
- Nov 2019
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of roflumilast vehicle cream in atopic dermatitis (AD) (3 arms), sponsored by Arcutis Biotherapeutics. Primary endpoint: Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at 4 weeks. Started May 2019; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03916081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916081.